1. Home
  2. VIRT vs NAMS Comparison

VIRT vs NAMS Comparison

Compare VIRT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIRT
  • NAMS
  • Stock Information
  • Founded
  • VIRT 2008
  • NAMS 2019
  • Country
  • VIRT United States
  • NAMS Netherlands
  • Employees
  • VIRT N/A
  • NAMS N/A
  • Industry
  • VIRT Investment Bankers/Brokers/Service
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VIRT Finance
  • NAMS Health Care
  • Exchange
  • VIRT Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • VIRT 2.8B
  • NAMS 3.1B
  • IPO Year
  • VIRT 2015
  • NAMS N/A
  • Fundamental
  • Price
  • VIRT $36.15
  • NAMS $38.48
  • Analyst Decision
  • VIRT Hold
  • NAMS Strong Buy
  • Analyst Count
  • VIRT 7
  • NAMS 10
  • Target Price
  • VIRT $41.43
  • NAMS $44.80
  • AVG Volume (30 Days)
  • VIRT 1.0M
  • NAMS 1.0M
  • Earning Date
  • VIRT 10-29-2025
  • NAMS 11-05-2025
  • Dividend Yield
  • VIRT 2.69%
  • NAMS N/A
  • EPS Growth
  • VIRT 132.69
  • NAMS N/A
  • EPS
  • VIRT 4.62
  • NAMS N/A
  • Revenue
  • VIRT $2,694,104,000.00
  • NAMS $35,243,000.00
  • Revenue This Year
  • VIRT N/A
  • NAMS N/A
  • Revenue Next Year
  • VIRT N/A
  • NAMS N/A
  • P/E Ratio
  • VIRT $7.72
  • NAMS N/A
  • Revenue Growth
  • VIRT 41.05
  • NAMS 4.91
  • 52 Week Low
  • VIRT $31.89
  • NAMS $14.06
  • 52 Week High
  • VIRT $45.77
  • NAMS $41.47
  • Technical
  • Relative Strength Index (RSI)
  • VIRT 63.50
  • NAMS 58.80
  • Support Level
  • VIRT $34.28
  • NAMS $34.50
  • Resistance Level
  • VIRT $35.43
  • NAMS $40.31
  • Average True Range (ATR)
  • VIRT 0.93
  • NAMS 2.45
  • MACD
  • VIRT 0.32
  • NAMS -0.13
  • Stochastic Oscillator
  • VIRT 94.48
  • NAMS 63.14

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: